Clinical Trial Update: A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis [Phase 2]

View source ↗

Summary

A Phase 2 open-label study evaluating the efficacy and safety of brepocitinib in adults with skin-predominant dermatomyositis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• Brepocitinib (brepocitinib)

Snippet

Sponsor: Priovant Therapeutics, Inc. | Conditions: Dermatomyositis, Dermatomyositis, Adult Type | Phase 2 | Status: COMPLETED